|
Mar 26
|
Stoke shares surge on updated results for Dravet drug
|
|
Mar 25
|
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
|
|
Mar 25
|
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
|
|
Mar 25
|
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Jan 11
|
Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results
|
|
Jan 8
|
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024
|
|
Jan 4
|
Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Jan 2
|
Why healthcare, biotech may be top plays for 2024: BTIG
|
|
Dec 1
|
Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting
|
|
Sep 5
|
Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress
|
|
Jun 21
|
Stoke Therapeutics, Inc. (STOK) Surges 6.3%: Is This an Indication of Further Gains?
|